Vitiligo treatment algorithm

2016 ◽  
Vol 19 (3) ◽  
pp. 167-169
Author(s):  
Konstantin M. Lomonosov ◽  
L. G Gereykhanova
Keyword(s):  
Treatment Strategy ◽  
Treatment Algorithm ◽  
Previous Treatment ◽  
Term Treatment ◽  
Early Termination ◽  
Treatment Regimens ◽  
Long Term Treatment

The treatment strategy ofpatients with vitiligo, including the identification of motivation for long-term treatment and informing patients to avoid false expectations as causes of dissatisfaction and early termination of the therapeutic course are described. The algorithm for the treatment of vitiligo consists of five successive stages. Each of them is sequentially applied with no previous treatment regimens efficiency or its maximum possible effect achievement. The use of the described treatment algorithm allows us to achieve in 70-80% of cases a marked repigmentation of vitiligo and to ensure long-term and often life-long remission of the disease.

scholarly journals Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?

2020 ◽  
Vol 18 (12.5) ◽  
pp. 1773-1776
Author(s):  
Shaji K. Kumar
Keyword(s):  
Multiple Myeloma ◽  
Chronic Disease ◽  
Treatment Strategy ◽  
Term Treatment ◽  
New Agents ◽  
Treatment Regimens ◽  
Recent Advances ◽  
Long Term Treatment ◽  
New Treatment

Although recent advances in the treatment of multiple myeloma have improved survival, it remains a chronic disease that requires a long-term treatment strategy. The key to achieving the best outcomes for patients is delivering the best “package” of treatment at a given stage. This means using optimal combinations that maximize benefit based on what patients have received previously and minimize treatment-related toxicity. Sequencing of regimens also plays an important role. As new agents and new classes of drugs continue to be approved for multiple myeloma, future strategies will use more individualized approaches to treatment.

scholarly journals Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice

2000 ◽  
Vol 44 (6) ◽  
pp. 1458-1462 ◽  
Author(s):  
Carolyn M. Shoen ◽  
Sharon E. Chase ◽  
Michelle S. DeStefano ◽  
Tami S. Harpster ◽  
Alex J. Chmielewski ◽  
...  
Keyword(s):  
Treatment Duration ◽  
Treatment Time ◽  
Term Treatment ◽  
Treatment Regimens ◽  
Short Course ◽  
Long Term Treatment ◽  
Nonculturable State ◽  
Time Required ◽  
Observation Period

ABSTRACT Previous experiments with rifalazil (RLZ) (also known as KRM-1648) in combination with isoniazid (INH) demonstrated its potential for short-course treatment of Mycobacterium tuberculosisinfection. In this study we investigated the minimum RLZ-INH treatment time required to eradicate M. tuberculosis in a murine model. RLZ-INH treatment for 6 weeks or longer led to a nonculturable state. Groups of mice treated in parallel were killed following an observation period to evaluate regrowth. RLZ-INH treatment for a minimum of 10 weeks was necessary to maintain a nonculturable state through the observation period. Pyrazinamide (PZA) was added to this regimen to determine whether the treatment duration could be further reduced. In this model, the addition of PZA did not shorten the duration of RLZ-INH treatment required to eradicate M. tuberculosis from mice. The addition of PZA reduced the number of mice in which regrowth occurred, although the reduction was not statistically significant.

scholarly journals Repeat interventions as a long-term treatment strategy in the management of progressive coronary artery disease

1996 ◽  
Vol 27 (6) ◽  
pp. 1398-1405 ◽  
Author(s):  
Kenneth G. Lehmann ◽  
Arthur C. Maas ◽  
Ron van Domburg ◽  
Pim J. de Feyter ◽  
Marcel van den Brand ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Treatment Strategy ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Artery Disease

Aripiprazole once monthly outpatient experience

2017 ◽  
Vol 41 (S1) ◽  
pp. S760-S760
Author(s):  
P. Sánchez Páez ◽  
J.L. Gómez Cano ◽  
L. Sánchez Flores ◽  
R. González Lucas ◽  
P. Artieda Urrutia
Keyword(s):  
Previous Treatment ◽  
Term Treatment ◽  
Tolerability Profile ◽  
Patient Profile ◽  
Co Morbidity ◽  
Long Term Treatment ◽  
Competing Interest ◽  
One Year ◽  
Image Position

IntroductionAripiprazole once monthly (AOM) is one of the most recently introduced antipsychotics with a different mechanism of action, which seems to bring clinical and tolerability implications [1].ObjectivesWe describe the patient profile that may benefit from AOM treatment.MethodsThis is a single-centre, retrospective, one year follow-up study of 13 cases of ambulatory AOM use. We analyze clinical and functional evolution, and the tolerability profile of patients in a real clinical practice basis.ResultsMean age was 53.69; 53.8% were males and 46.2% females. The most frequent diagnosis was Schizophrenia and other chronic psychosis (69.3%). Only 7.7% had co-morbidity with substance use disorder (cocaine); 61.6% were on previous treatment with other injectable anti-psychotics; 84,6% of the sample received AOM as monotherapy. Reasons for switching to AOM are shown on Fig. 1. Events during switching are shown on Fig. 2. Outcomes with AOM long-term treatment were positive in 84.61% of cases and are shown on Fig. 3.ConclusionsSwitching to AOM could be considered as a good strategy to improve tolerability, functionality and ultimately adherence to treatment in patients in middle age of life with a chronic psychotic disorder [2].Fig. 1Reasons for switching.Fig. 2Events during switching.Fig. 3Outcomes with AOM.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice

1999 ◽  
Vol 43 (10) ◽  
pp. 2356-2360 ◽  
Author(s):  
Anne M. J. A. Lenaerts ◽  
Sharon E. Chase ◽  
Alex J. Chmielewski ◽  
Michael H. Cynamon
Keyword(s):  
Term Treatment ◽  
New Drugs ◽  
Intermittent Treatment ◽  
Bacterial Regrowth ◽  
Treatment Regimens ◽  
Weekly Treatment ◽  
Long Term Treatment ◽  
Apparent Clearance ◽  
Antituberculosis Chemotherapy

ABSTRACT Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.

Efficacy of Long Term Treatment Regimens on Cyclic Vomiting Syndrome in Adults

2008 ◽  
Vol 103 ◽  
pp. S464
Author(s):  
Reza Hejazi ◽  
Teri Lavenbarg ◽  
Savio Reddymasu ◽  
Pernilla Foran ◽  
Richard McCallum
Keyword(s):  
Term Treatment ◽  
Cyclic Vomiting Syndrome ◽  
Treatment Regimens ◽  
Long Term Treatment ◽  
Cyclic Vomiting

scholarly journals Treatment strategy for patients with esthesioneuroblastoma and long-term outcomes

2020 ◽  
Vol 10 (3) ◽  
pp. 27-40
Author(s):  
E. R. Oganyan ◽  
A. M. Mudunov ◽  
S. B. Alieva ◽  
N. A. Pirogova ◽  
A. A. Markovich ◽  
...  
Keyword(s):  
Treatment Strategy ◽  
Locally Advanced ◽  
Term Treatment ◽  
Comprehensive Treatment ◽  
Ki 67 ◽  
Regional Lymph Nodes ◽  
Tumor Spread ◽  
Study Objective ◽  
Long Term Treatment

The study objective is to summarize clinical experience in the treatment of esthesioneuroblastoma (ENB) accumulated by specials at N.N. Blokhin National Medical Research Center of Oncology.Materials and methods. We analyzed the data of 115 ENB patients who had undergone treatment between 1965 and 2019.Results. The 15-year overall survival rate was 1.2–1.7 times higher in patients receiving comprehensive treatment (47.7 ± 11.3 %) than in those receiving other types of therapy. In addition to that, comprehensive treatment ensured the highest rates of 3-year, 5-year, and 10-year relapse-free survival (49.3 ± 11.8 %), as well as the longest median survival (7.2 years). Chemoradiotherapy was effective in 34.8 % of patients with locally advanced ENB, while in 9 out of 45 patients (20.0 %), it resulted in partial response, which suggest that such treatment can control aggressive disease course and increase survival. Surgical treatment (alone or in combination with chemotherapy and radiotherapy) was indicated for 64 patients. However, only in 43 of them (67.1 %), it was performed as originally planned. Five patients (7.8 %) had partially radical surgeries and sixteen patients (25.1 %) had non-radical surgeries.Conclusion. The most effective treatment strategy for locally advanced ENB is a combination of surgery, chemotherapy, and radiotherapy. Chemoradiotherapy at the first stage followed by surgery was found to be an optimal treatment scheme. Tumor sensitivity to chemo- and radiotherapy affects both short-term and long-term treatment outcomes. Partially radical surgeries for locally advanced ENB are acceptable if conservative treatment is planned after operation. Treatment strategy should depend on the tumor spread (stage), grade, and proliferative activity, as well as patient’s age, somatic status, and comorbidities. Multivariate analysis has demonstrated that none of treatment methods decrease survival. The most significant factors negatively affecting the prognosis were as follows: T3–4 tumor, involvement of regional lymph nodes before treatment initiation, distant metastasis, grade IV tumor, and Ki-67 index >21 %.

Acupuncture and Self Acupuncture for Long Term Treatment of Vasomotor Symptoms in Cancer Patients - Audit and Treatment Algorithm

2005 ◽  
Vol 23 (4) ◽  
pp. 171-180 ◽  
Author(s):  
Jacqueline Filshie ◽  
Tara Bolton ◽  
Doreen Browne ◽  
Sue Ashley
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Hormone Replacement ◽  
Treatment Algorithm ◽  
Term Treatment ◽  
Vasomotor Symptoms ◽  
Hot Flushes ◽  
Long Term Treatment

Introduction Since hormone replacement therapy given for long periods is now recognised to produce serious side effects, patients with troublesome vasomotor symptoms are increasingly using non-hormonal treatment including acupuncture. Several randomised controlled trials have shown that acupuncture reduces menopausal symptoms in patients experiencing the normal climacteric. It may have this effect by raising serotonin levels which alter the temperature set point in the hypothalamus. Vasomotor symptoms can be extreme in breast cancer patients and patients with prostate cancer who are undergoing anticancer therapy. The safety of some herbal medicines and phytoestrogens has been questioned, as they could potentially interfere adversely with the bioavailability of tumouricidal drugs. A previous study reports short term benefit from acupuncture, and the aim of this report is to describe our approach to long term treatment. Acupuncture Approach After piloting several approaches, six weekly treatments were given initially at LI4, TE5, LR3 and SP6 and two upper sternal points, but avoiding any limb with existing lymphoedema or prone to developing it. If there were no contraindications, patients were given clear instructions on how to perform self acupuncture using either semi-permanent needles or conventional needling at SP6, weekly for up to six years, for long term maintenance. Audit Methods and Results A retrospective audit of electronic records was carried out by a doctor not involved in treatment. A total of 194 patients were treated, predominantly with breast and prostate cancer. One hundred and eighty two patients were female. The number of pre-treatment hot flushes per day was estimated by the patient: in the 159 cases providing adequate records, the mean was 16 flushes per day. Following treatment, 114 (79%) gained a 50% or greater reduction in hot flushes and 30 (21%) a less than 50% reduction. Treatment was abandoned in those who responded poorly or not at all. The duration of treatment varied from one month to over six years with a mean duration of nine months. Seventeen patients (9%) experienced minor side effects over the six year period, mostly minor rashes; one patient described leg swelling but this was likely to be due to a concurrent fracture. Conclusion Acupuncture including self acupuncture is associated with long term relief of vasomotor symptoms in cancer patients. Treatment is safe and costs appear to be low. An algorithm is presented to guide clinical use. We recommend the use of self acupuncture with needles at SP6 in preference to semi-permanent needles in the first instance, but poor responders use indwelling studs if they fail to respond adequately to self acupuncture with regular needles. Point location may be of less importance than the overall ‘dose’, and an appropriate minimum dose may be required to initiate the effect.

Sign in / Sign up

Export Citation Format

Share Document